US OptionsDetailed Quotes
NVCR241018C19000
- 0.15
- +0.10+200.00%
15min DelayClose Oct 11 16:00 ET
0.15High0.10Low
0.10Open0.05Pre Close48 Volume584 Open Interest19.00Strike Price530.00Turnover126.59%IV21.59%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.1305Delta0.0866Gamma105.00Leverage Ratio-0.0461Theta0.0003Rho13.70Eff Leverage0.0041Vega
Novocure Stock Discussion
Sign in to post a comment
$Apellis Pharmaceuticals (APLS.US)$👈 wallstreet seems to like this stock still giving them a nice price target
$Emergent BioSolutions (EBS.US)$
$Novocure (NVCR.US)$
$Emergent BioSolutions (EBS.US)$
$Novocure (NVCR.US)$
1
3
$Novocure (NVCR.US)$ I'm in. buy rating and PT out 😁Wells Fargo Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $40
2
$Emergent BioSolutions (EBS.US)$👀 big news out WHO Says Expert Committee Will Propose Adopti - moomoo $Apellis Pharmaceuticals (APLS.US)$ $Puma Biotechnology (PBYI.US)$ $Novocure (NVCR.US)$
1
$Novocure (NVCR.US)$ pt anyone?
2
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Novocure (NVCR.US)$ I placed limit buy @13.1 but got filled at 13.299, I noticed this many times in this app, they are causing slippage, anyone noticed same?
2
$iBio Inc (IBIO.US)$ IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for obesity and cardiometabolic diseases.
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
DRCT: -49% | Direct Digital Holdings shares are trading lower after the company reported worse-than-expected Q4 financial results.
NVCR: 42% | Novocure shares are trading higher after the company's METIS Phase 3 trial met primary endpoint, demonstrating statistically significant extension in time to intracranial ...
Morning Movers
Gapping up
$Deutsche Bank (DB.US)$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co (MRK.US)$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology (DJT.US)$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood (HOOD.US)$ stock climbed 6...
Gapping up
$Deutsche Bank (DB.US)$ shares rose 3% after Morgan Stanley upgraded the stock to overweight, suggesting further potential growth following a strong performance in 2024.
$Merck & Co (MRK.US)$ stock rose 4.8% after its drug for treating a rare lung disease received FDA approval.
$Trump Media & Technology (DJT.US)$ stock jumped 14%, following gains after its Nasdaq debut.
$Robinhood (HOOD.US)$ stock climbed 6...
34
Key Takeaway
GameStop ( $GameStop (GME.US)$ ) and Forge Global ( $Forge Global (FRGE.US)$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure (NVCR.US)$ ) surges 30% on positive trial results.
Merck ( $Merck & Co (MRK.US)$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
GameStop ( $GameStop (GME.US)$ ) and Forge Global ( $Forge Global (FRGE.US)$ ) face pre-market declines of 17% and 11% respectively, while Novocure ( $Novocure (NVCR.US)$ ) surges 30% on positive trial results.
Merck ( $Merck & Co (MRK.US)$ ) gains 4% after FDA approval of its treatment, highlighting a day of significant volatility and strategic moves in the U.S. stock market.
A Glimpse into Quarter-End Moves
As the curtains draw near on...
1
The 23% annualized share price decline underscores the risk of investing in unprofitable firms. The company's poor performance last year may suggest ongoing issues, as it was worse than the 11% annualized loss over the past five years. Prolonged share price weakness can be a negative indicator, though contrarian investors might want to investigate the stock for a potential turnaround.
1
No comment yet
George Soros II : LFGGG
EZ_money OP George Soros II :
